Caden Cotnoir was watching a video on TikTok when something went horribly wrong. Source: WMUR
Caden Cotnoir was watching a video on TikTok when something went horribly wrong. Source: WMUR
NETSTREIT Corp. (the "Company") announced today that it has closed its previously announced public offering of 10,915,688 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $18.65 per share. Gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $203.6 million.
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Ebang International Holdings, Inc. ("Ebang" or the "Company") (NASDAQ: EBON) securities from June 26, 2020 through April 5, 2021, inclusive (the "Class Period"). Investors have until June 7, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that class action lawsuits have been filed on behalf of stockholders of Ebix, Inc., EHang Holdings Limited, Renewable Energy Group, Inc., and XL Fleet Corp. Investors have until the deadlines below to apply to the Court to be appointed as lead plaintiff in the lawsuit. Additional information about each case can be found at the links provided below. Ebix, Inc. (“Ebix” or the “Company”) (NASDAQ: EBIX) Class Period: November 9, 2020 to February 19, 2021 Lead Plaintiff Deadline: April 23, 2021 On February 19, 2021, after the market closed, Ebix revealed that its independent auditor, RSM US LLP (“RSM”), resigned “as a result of being unable, despite repeated inquiries, to obtain sufficient appropriate audit evidence that would allow it to evaluate the business purpose of significant unusual transactions that occurred in the fourth quarter of 2020” related to the Company’s gift card business in India. RSM had also stated that there was a material weakness related to Ebix’s failure to design controls “over the gift or prepaid card revenue transaction cycle sufficient to prevent or detect a material misstatement.” In addition, Ebix and RSM disagreed over the accounting treatment of $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel in December 2020. On this news, the Company’s share price declined by $20.24 per share, or approximately 40%, to close at $30.50 per share on February 22, 2021, on unusually heavy trading volume. The lawsuit alleges that throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix’s gift card business in India during the fourth quarter of 2020; (2) that there was a material weakness in the Company’s internal controls over the gift or prepaid revenue transaction cycle; and (3) that the Company’s independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For additional information on the Ebix lawsuit please visit this website. EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH) Class Period: December 9, 2019 to February 16, 2021 Lead Plaintiff Deadline: April 19, 2021 On February 16, 2021, analyst Wolfpack Research published a research report entitled “EHang: A Stock Promotion Destined to Crash and Burn.” Citing “extensive evidence” including “behind-the-scenes photographs, recorded phone calls, and videos of on-site visits to EH’s various facilities,” the report alleged that EHang is “an elaborate stock promotion, built on largely fabricated revenues based on sham sales contracts with a customer [Shanghai Kunxiang Intelligent Technology Co., Ltd.] who appears to us to be more interested in helping inflate the value of its investment in EH…than about buying its products.” Wolfpack Research also noted that “in just 14 months as a publicly traded company, EH’s PR team has put out 50 press releases…However, EH’s constant stream of press releases are easily proven untrue.” Finally, the report alleged that Wolfpack Research “obtained Chinese court records which show that EH’s ADRs may already be in serious jeopardy due to legal issues in China.” On this news, the Company’s share price declined by $77.79 per share, or approximately 62.7%, to close at $46.30 per share on February 16, 2021, thereby injuring investors. The lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s purported regulatory approvals in Europe and North America for its EH216 were for use as a drone, and not for carrying passengers; (2) its relationship with its purported primary customer is a sham; (3) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (4) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times. For additional information on the EHang lawsuit please visit this website. Renewable Energy Group, Inc. (“Renewable Energy” or the “Company”) (NASDAQ: REGI) Class Period: May 3, 2018 to February 25, 2021 Lead Plaintiff Deadline: May 3, 2021 On February 25, 2021, after the market closed, Renewable Energy issued a press release announcing its fourth quarter and full year 2020 financial results. Therein, the Company revealed that it would restate “$38.2 million in cumulative revenue from January 2018 through September 30, 2020” because Renewable Energy was not the “proper claimant for certain BTC payments on biodiesel it sold between January 1, 2017 and September 30, 2020.” Renewable Energy further stated that it had reached an agreement with the Internal Revenue Service “on a $40.5 million assessment, excluding interest” to correct these claims. On this news, the Company’s share price declined by $8.17 per share, or approximately 9.5%, to close at $77.77 per share on February 26, 2021, on unusually heavy trading volume. The lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that due to failures in the diesel additive system, petroleum diesel was not periodically added to certain loads by the Company and was instead added by the Company’s customers; (2) that, as a result, Renewable Energy was not the proper claimant for certain BTC payments on biodiesel it sold between January 1, 2017 and September 30, 2020; (3) that, as a result, Renewable Energy’s revenue and net income were overstated for certain periods; (4) that there was a material weakness in the Company’s internal control over financial reporting related to the purchase and use of the petroleum diesel gallons when blending with biodiesel; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For additional information on the Renewable Energy lawsuit please visit this website. XL Fleet Corp. (“XL” or the “Company”) (NYSE: XL) Class Period: October 2, 2020 to March 2, 2021 Lead Plaintiff Deadline: May 7, 2021 On March 3, 2021, Muddy Waters Research published a report entitled “XL Fleet Corp. (NYSE: XL): More SPAC Trash,” alleging, among other things, that salespeople “were pressured to inflate their sales pipelines materially in order to mislead XL’s board and investors” and that “customer reorder rates are in reality quite low” due to “poor performance and regulatory issues.” Citing interviews with former employees, the report alleged that “at least 18 of 33 customers XL featured were inactive.” Muddy Waters also claimed that XL has “weak technology” and that “XL’s announcement of future class 7-8 upfits seems highly promotional” because the task is “too technologically complex for XL engineers to deliver on the promised timeline.” On this news, the Company’s stock price declined by $2.09 per share, or approximately 13%, to close at $13.86 per share on March 3, 2021, on unusually heavy trading volume. The share price continued to decline by $2.69 per share, or approximately 19.4%, over two consecutive trading days to close at $11.17 per share on March 5, 2021, on unusually heavy trading volume. The lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that XL Fleet’s salespeople were pressured to inflate their sales pipelines to boost the Company’s reported sales and backlog; (2) that at least 18 of the 33 customers that XL featured were inactive and had not placed an order since 2019; (3) that XL’s technology had been materially overstated and offered only 5% to 10% of fleet savings; (4) that XL lacks the supply chain and engineers to roll out new products on the announced timelines; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For additional information on the XL lawsuit please visit this website. About Kirby McInerney LLP: Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. ContactsKirby McInerney LLPThomas W. Elrod, Esq., (212) firstname.lastname@example.org www.kmllp.com
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies. “Chase is a highly seasoned and pragmatic General Counsel and business leader with a broad background spanning both biotech and technology companies that will help to position Oncternal for our next stage of growth,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “I am excited to join the Oncternal team at this critical juncture. The Company is advancing an attractive and differentiated pipeline of ROR1-targeting immunotherapies and oncology products in areas of high unmet need,” said Mr. Leavitt. “I look forward to collaborating with this highly focused team to develop new cancer treatments while positioning Oncternal to become a leading player in the oncology space.” Mr. Leavitt served as General Counsel and Corporate Secretary of Lineage Cell Therapeutics, Inc., a publicly traded biotechnology company, from May 2019 to April 2021 where he focused on public company compliance and governance, business development transactions, financing activities, litigation, and managed all other legal needs of the company. From June 2018 to May 2019, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded biotechnology company. From May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel of Switch, Inc., a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014, Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets transactions. Mr. Leavitt received a B.S. degree in business administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California. Equity Inducement GrantOncternal granted an inducement award on April 12, 2021 to Chase Leavitt under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The inducement award to Mr. Leavitt consists of options to purchase 235,000 shares of Oncternal common stock. The options have a 10-year term and an exercise price equal to $6.76 per share, the fair market value of Oncternal’s common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of Mr. Leavitt’s employment start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal’s compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and was granted as an inducement material to Mr. Leavitt entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4). About Oncternal TherapeuticsOncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. We are also developing a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at www.oncternal.com. Forward-Looking Information Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. Forward-looking statements include statements regarding Oncternal’s beliefs, goals, intentions and expectations including, without limitation, Oncternal’s expectations regarding its growth and development plans. Forward-looking statements are subject to risks and uncertainties inherent in Oncternal’s business, which include, but are not limited to: the risk that unforeseen adverse reactions or side effects may occur in the course of developing and testing product candidates such as cirmtuzumab, TK216, ROR1 CAR-T and Oncternal’s other product candidates, which could adversely impact the company’s ability to complete clinical trials and obtain regulatory approval for such product candidates; Oncternal has encountered delays, and may encounter additional delays or difficulties, in completing preclinical studies and enrolling and retaining patients in its clinical trials as a result of the COVID-19 pandemic; the COVID-19 pandemic may disrupt Oncternal’s business operations, increasing its costs; uncertainties associated with the clinical development and process for obtaining regulatory approval of cirmtuzumab, TK216 and Oncternal’s other product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; Oncternal’s dependence on the success of cirmtuzumab, TK216, ROR1 CAR-T and its other product development programs; the risk that the approval of one of Oncternal’s product candidates may be blocked for seven years if a competitor obtains approval of the same drug or biologic, as defined by the U.S. Food and Drug Administration, or if its product candidate is determined to be contained within the competitor’s product for the same indication or disease; the risk that competitors may develop technologies or product candidates more rapidly than Oncternal, or that are more effective than Oncternal’s product candidates, which could significantly jeopardize Oncternal’s ability to develop and successfully commercialize its product candidates; Oncternal’s limited operating history and the fact that it has incurred significant losses, and expects to continue to incur significant losses for the foreseeable future; the risk that the company will have insufficient funds to finance its planned operations and may not be able to obtain sufficient additional financing when needed or at all as required to achieve its goals, which could force the company to delay, limit, reduce or terminate its product development programs or other operations; the risk that the benefits associated with orphan drug designation may not be realized, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained; the risk that, if an orphan designated product, including cirmtuzumab, receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity; the possibility that competitors may receive approval of different products for the indication for which an orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity; and other risks described in the company’s prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Oncternal Contacts: Company ContactRichard Vincent email@example.com Investor ContactCorey Davis, Ph.D.LifeSci Advisors212firstname.lastname@example.org Source: Oncternal Therapeutics, Inc.
COLUMBIA, Md., April 12, 2021 (GLOBE NEWSWIRE) -- W. R. Grace & Co. (NYSE:GRA), the leading independent supplier of polyolefin catalyst technology and polypropylene (PP) process technology, has licensed its UNIPOL® PP Process Technology to the new MTO Gas Chemical Complex located in the Bukhara region of Uzbekistan to Enter Engineering. The UNIPOL® PP Technology facility is expected to be launched by-2025 and will include one reactor line with the capability to produce 257KTA of polypropylene. Enter Engineering Pte. Ltd., one of the largest construction companies in the region, will act as a licensee on behalf of the JV Jizzakh Petroleum LLC who will own and operate the Gas Chemical Complex. Grace's all gas-phase UNIPOL® PP Process Technology delivers technology, innovation, and services for plant lifetime performance. The versatile process technology provides the broadest range of PP homopolymers, random copolymers, and impact copolymers in the industry. The UNIPOL® PP technology process is a state-of-the-art engineering technology that achieves mechanical and operational simplicity and delivers leading total installed cost and operating expense, accelerated project schedules, fast startups, grade transitions, and business results. The process technology, coupled with Grace’s proprietary catalyst and donor systems and the UNIPOL UNIPPAC® process control software, allows for maximum performance. “We welcome Enter Engineering and Jizzakh Petroleum into the UNIPOL® PP Technology Family and we are excited to launch our first UNIPOL® PP process technology in Uzbekistan,” Laura Schwinn, President of Grace’s Specialty Catalysts business said. Schwinn added, “We are committed to their success and our team of experts are ready to support this project for years to come - from construction to ongoing operations and optimization. We look forward to seeing Jizzakh Petroleum becoming the premier supplier of polypropylene resins in the region.” All UNIPOL® PP Technology licensees can take advantage of Grace’s PPartner Program™ which provides continuous process and product improvements, access to global technical services, catalyst development updates, and ongoing support for the lifetime of the plant. Visit Grace’s website for more information about Grace polyolefin catalysts and process technology. About Grace’s UNIPOL® PP Process Technology Grace is the leading supplier of polyolefin catalyst technology and has the broadest portfolio of polyolefin catalyst technologies of any independent polyethylene/polypropylene catalyst producer. Grace is an industry leader in offering UNIPOL® PP Process Technology, 6th Generation non-phthalate CONSISTA® catalysts and donors, and UNIPOL UNIPPAC® Process Control software. UNIPOL® and UNIPOL UNIPPAC® are trademarks of The Dow Chemical Company or an affiliated company of Dow. W. R. Grace & Co.-Conn. and/or its affiliates are licensed to use the UNIPOL® and UNIPOL UNIPPAC® trademarks in the area of polypropylene. About Grace Built on talent, technology, and trust, Grace is a leading global supplier of catalysts and engineered materials. The company’s two industry-leading business segments—Catalysts Technologies and Materials Technologies—provide innovative products, technologies, and services that enhance the products and processes of our customers around the world. With approximately 3,900 employees, Grace operates and/or sells to customers in over 70 countries. More information about Grace is available at grace.com. This announcement contains forward-looking statements, that is, information related to future, not past, events. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “expects,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. Forward-looking statements include, without limitation, expected financial positions; results of operations; cash flows; financing plans; business strategy; operating plans; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; and markets for securities. For these statements, Grace claims the protections of the safe harbor for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Like other businesses, Grace is subject to risks and uncertainties that could cause its actual results to differ materially from its projections or that could cause other forward-looking statements to prove incorrect. Factors that could cause actual results to differ materially from those contained in the forward-looking statements include, without limitation: risks related to foreign operations, especially in emerging regions; the costs and availability of raw materials, energy and transportation; the effectiveness of its research and development and growth investments; acquisitions and divestitures of assets and businesses; developments affecting Grace’s outstanding indebtedness; developments affecting Grace's pension obligations; its legal and environmental proceedings; environmental compliance costs; the inability to establish or maintain certain business relationships; the inability to hire or retain key personnel; natural disasters such as storms and floods, and force majeure events; changes in tax laws and regulations; international trade disputes, tariffs, and sanctions; the potential effects of cyberattacks; and those additional factors set forth in Grace's most recent Annual Report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, which have been filed with the Securities and Exchange Commission and are readily available on the internet at www.sec.gov. Reported results should not be considered as an indication of future performance. Readers are cautioned not to place undue reliance on Grace's projections and forward-looking statements, which speak only as of the dates those projections and statements are made. Grace undertakes no obligation to release publicly any revision to the projections and forward-looking statements contained in this announcement, or to update them to reflect events or circumstances occurring after the date of this announcement. Media RelationsCaitlin LeopoldT +1 email@example.com Investor Relations Jason Hershiser +1 410 531 8835 Jason.firstname.lastname@example.org
First Trust Advisors L.P. ("FTA") announces the declaration of the monthly distributions for certain exchange-traded funds advised by FTA.
Chelsea defender Xavier Mbuyamba on Monday made his long-awaited debut for the club following a summer move from Barcelona. Injuries and fitness problems have hampered his progress, but he was named on the bench as Chelsea faced Southampton in Premier League 2 and came on with a little under half an hour to play and scored just four minutes later. Mbuyamba spent the majority of his youth career at Dutch outfit MMV Maastricht, making his debut in a second-tier Eerste Divisie game in November 2018 as a 16-year-old.
DENVER, April 12, 2021 (GLOBE NEWSWIRE) -- National Bank Holdings Corporation (NYSE: NBHC) expects to report its first quarter financial results after the markets close on Thursday, April 22, 2021. Management will host a conference call to review the results at 11:00 a.m. Eastern Time on Friday, April 23, 2021. Interested parties may listen to this call by dialing (877) 272-6762/ (615) 800-6832 (International) using the Conference ID of 9588935 and asking for the NBHC First Quarter Earnings conference call. A telephonic replay of the call will be available beginning approximately four hours after the call’s completion through May 6, 2021, by dialing (855) 859-2056 (United States) / (404) 537-3406 (International) using the Conference ID of 9588935. The earnings release and an on-line replay of the call will also be available on the Company’s website at www.nationalbankholdings.com by visiting the investor relations area. About National Bank Holdings Corporation National Bank Holdings Corporation is a bank holding company created to build a leading community bank franchise delivering high quality client service and committed to stakeholder results. Through its bank subsidiary, NBH Bank, National Bank Holdings Corporation operates a network of 89 banking centers, serving individual consumers, small, medium and large businesses, and government and non-profit entities. Its banking centers are located in its core footprint of Colorado, the greater Kansas City region, Texas, Utah and New Mexico. Its comprehensive residential mortgage banking group primarily serves the bank's core footprint. NBH Bank operates under the following brand names: Community Banks of Colorado and Community Banks Mortgage, a division of NBH Bank, in Colorado, Bank Midwest and Bank Midwest Mortgage in Kansas and Missouri, and Hillcrest Bank and Hillcrest Bank Mortgage in Texas, Utah and New Mexico. Additional information about National Bank Holdings Corporation can be found at www.nationalbankholdings.com. For more information visit: cobnks.com, bankmw.com, hillcrestbank.com or nbhbank.com. Or, follow us on any of our social media sites: Community Banks of Colorado: facebook.com/cobnks, twitter.com/cobnks, instagram.com/cobnks; Bank Midwest: facebook.com/bankmw, twitter.com/bank_mw, instagram.com/bankmw;Hillcrest Bank: facebook.com/hillcrestbank, twitter.com/hillcrest_bank; NBH Bank: twitter.com/nbhbank; or connect with any of our brands on LinkedIn. Contact: Analysts/Institutional Investors:Media:Aldis Birkans, 720-554-6640Jody Soper, 303-784-5925Chief Financial OfficerChief Marketing Officerir@nationalbankholdings.com Jody.Soper@nbhbank.com Source: National Bank Holdings Corporation
(Bloomberg) -- Treasury Secretary Janet Yellen will decline to name China as a currency manipulator in her first semiannual foreign-exchange report, according to people familiar with the matter, a move that allows the U.S. to sidestep a fresh clash with Beijing.The report, which is not yet finalized, is due on Thursday, although it is unclear when the department will release it. During the Trump era, the Treasury Department was accused of politicizing the report after it abruptly designated China a manipulator in mid-2019 outside its usual release schedule, only to lift the label five months later to win concessions in a trade deal.A Treasury spokeswoman declined to comment. The offshore yuan extended its intraday gain slightly following the news, strengthening around 0.2% to touch a new high for the day of around 6.5462 per dollar.Yellen’s team has also discussed the possibility of reversing a 2019 Trump administration move to lower thresholds for determining whether an economy is manipulating its currency for competitive advantage, the people said on condition of anonymity because the talks are private. A rollback could lead to the agency cutting the number of nations it scrutinizes by nearly half, they said.The Biden administration is looking to hold China accountable for what it says are unfair trade practices, along with other issues such as human-rights violations, while reviewing what to do with tariffs slapped on billions of dollars of Chinese goods by former President Donald Trump.Designation as a currency manipulator comes with no immediate penalties but can rattle financial markets. The law requires the administration to engage with the countries to address the perceived exchange-rate imbalance. Penalties, including exclusion from U.S. government contracts, could be applied after a year unless the label were removed.While China is set to escape a manipulation tag in the upcoming report, Treasury officials are concerned that the nation is masking currency intervention through activities at state-owned banks, according to the people familiar with the matter.During her confirmation hearing in January, Yellen told lawmakers that the U.S. “should oppose” attempts by other nations to game their currencies.She also hinted at changing the criteria of the currency report, saying that bilateral trade deficits shouldn’t be seen as “a single catch-all metric.”In the last report during the Trump administration, then-Treasury Secretary Steven Mnuchin labeled Switzerland a currency manipulator and placed India on its watch list for closer scrutiny. Since then, officials in those nations have largely ignored the U.S. and are continuing aggressive moves, and indication that the report is no longer effective as it once was.‘Rebuild Credibility’Under the Trump administration there was an “ad hoc” interpretation of the manipulation criteria, according to Eswar Prasad, an economist at Cornell University who formerly worked in the International Monetary Fund’s China division.In 2017, Mnuchin placed China on its so-called watch list of countries receiving heightened scrutiny for triggering one out of three of the criteria, rather than the two that is the standard laid out in the report.Now Treasury needs to “rebuild credibility for the report by using a more sensible set of criteria and applying them in a consistent manner across countries rather than change the process to specifically target a certain country,” Prasad said.The Treasury’s currency report has had special resonance in Asia, home to eight of the 10 members of the December report’s monitoring list in addition to Vietnam’s manipulator tag. Governments in the region have been burdened by U.S.-China tensions throughout the trade war begun under the Trump administration, caught between a critical security and investment partner and their biggest economic partner.They’re now bracing for the potential that President Joe Biden’s White House will keep up the pressure not just on China but on some of its traditional allies or friends in the region, including through assessments of domestic currency policies.(Updates with market reaction in third paragraph, economist’s comment under subheadline.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Follow the latest developments live
Estrella Media, a leading vertically integrated, multi-platform, Spanish-language media company, announced today that beloved, iconic Mexican actress Angélica Vale is joining the EstrellaTV network as host of the new original dating series La Máscara Del Amor (The Mask of Love). The series is currently in production at Estrella Studios in Burbank, CA.
First Trust Energy Income and Growth Fund (the "Fund") (NYSE American: FEN) has declared the Fund's regularly scheduled quarterly distribution of $0.30 per share. The distribution will be payable on April 30, 2021, to shareholders of record as of April 23, 2021. The ex-dividend date is expected to be April 22, 2021. The quarterly distribution information for the Fund appears below.
Tim Bouchet, Pride Mountain Vineyards Director of Sales and Hospitality, joined Yahoo Finance Live to discuss how the winey has fared during COVID-19 and the protocols in place to keep customers safe during wine tastings.
Daunte Wright was killed by police on Sunday as the murder trial of former officer Derek Chauvin heads towards a conclusion
Air Lease Corporation (NYSE: AL) announced the delivery of one new Airbus A321-200neo LR aircraft on long-term lease to Air Astana. This aircraft, featuring Pratt & Whitney PW1133G engines, is the fifth new A321-200neo LR to deliver to Air Astana from ALC’s order book with Airbus. In addition to the five A321-200neo LRs, Air Astana also has one A320-200, two A320-200neos and one A321-200neo on long-term lease from ALC.
RS-68A Acceptance Test at SSC 4-12-21 Aerojet Rocketdyne’s RS-68A rocket engine successfully completed its final acceptance test April 12, 2021, on the B-1 test stand at NASA’s Stennis Space Center in Mississippi. The RS-68A powers the United Launch Alliance Delta IV Heavy rocket to send critical spacecraft into orbit. Image Credit: NASA Stennis STENNIS SPACE CENTER, Miss., April 12, 2021 (GLOBE NEWSWIRE) -- Today, the world’s most powerful hydrogen-fueled rocket engine built by Aerojet Rocketdyne, the RS-68A, completed its final hot-fire acceptance test for use on the United Launch Alliance (ULA) Delta IV Heavy launch vehicle on the B-1 Test Stand at NASA’s Stennis Space Center in Mississippi. ULA’s Delta IV Heavy rocket uses three Aerojet Rocketdyne RS-68A engines; one on each of its three common booster cores to launch the nation’s most critical spacecraft into orbit. The three RS-68A engines combine to generate more than two million pounds of thrust for the Delta IV Heavy. “The throttleable RS-68A engine has been the centerpiece of the Delta IV Heavy rocket for more than 15 years,” said Eileen P. Drake, Aerojet Rocketdyne CEO and president. “We are very proud of the 65 engines flown to date and their flawless performance record.” Conceived using a simplified design approach to lower cost while maintaining its overall reliability, the original variant of the engine, the RS-68, was first tested at Edwards Air Force Base in California; testing later moved to Stennis in 2000. The RS-68 powered Delta IV made its inaugural flight in 2002. “We’ve continued to improve the RS-68 engine, which today remains the most powerful hydrogen-fueled rocket engine in the world,” said Jim Maser, Aerojet Rocketdyne senior vice president of Space. “This engine was developed entirely with company funds to be a very cost competitive and extremely reliable booster engine.” The upgraded RS-68A, which generates 705,000 pounds of thrust at sea level, completed its first test firing in September 2008, was certified in April 2011 and made its inaugural flight in June 2012. “Our RS-68 test partnership with Aerojet Rocketdyne spans more than 20 years and the final RS-68 hot-fire test closes out a historic chapter in propulsion testing at Stennis Space Center,” said NASA’s Stennis Space Center Director Richard Gilbrech. “The RS-68 was the first engine to be both assembled and tested at Stennis. While this particular test project is ending, we look forward to continued work with Aerojet Rocketdyne on future endeavors.” In addition to launching numerous payloads supporting the U.S. Air Force Space Command and the National Reconnaissance Office, the Delta IV Heavy carried NASA’s Orion spacecraft on the EFT-1 mission in December 2014, and launched the Parker Solar Probe on its mission to unlock the mysteries of the Sun in August 2018. The Delta IV Heavy, powered by the RS-68A engine, continues to be the primary heavy-lift launch vehicle for the United States. The Delta IV Heavy has four launches remaining. Aerojet Rocketdyne’s work at NASA’s Stennis Space Center continues with final assembly and test of the RS-25 engine that powers the core stage of America’s next super heavy-lift rocket, the Space Launch System (SLS). The most powerful rocket ever built, SLS will send humans to explore the Moon as part of the NASA’s Artemis program. About Aerojet Rocketdyne: Aerojet Rocketdyne, a subsidiary of Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD), is a world-recognized aerospace and defense leader that provides propulsion systems and energetics to the space, missile defense and strategic systems, and tactical systems areas, in support of domestic and international customers. For more information, visit www.Rocket.com and www.AerojetRocketdyne.com. Follow Aerojet Rocketdyne and CEO Eileen Drake on Twitter at @AerojetRdyne and @DrakeEileen. Media Contacts:Mary Engola, Aerojet Rocketdyne, 571-289-1371Mary.Engola@rocket.comTodd McConnell, Aerojet Rocketdyne, 561-882-5395Todd.McConnell@rocket.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/43cc7d18-fc4d-4047-912e-a1dc4d13da37
Calexo’s “Watercolors” Cannabis Beverages to be Produced at Tinley’s Long Beach Facility Calexo ‘Watercolors’ (proposed products and packaging shown), and a new range of preservative-free juice-based products in cans will be produced at The Tinley Beverage Company’s facility in Long Beach, California. THIS NEWS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. PERSONS LOS ANGELES and TORONTO, April 12, 2021 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (CSE:TNY, OTC:TNYBF) (“Tinley's” or “Company”) is pleased to announce that Los Angeles-based Calexo will produce three new zero-calorie sparkling drinks in bottles, and four preservative-free juice beverages in cans at the Company’s Long Beach facility. The Company is also pleased to provide updates on distribution of its branded products and its Long Beach distribution facility buildout. Calexo’s new line of cannabis-infused sparkling waters, branded as “Watercolors”, will be crafted with natural botanicals and 5mg nano-emulsified THC per 12oz. bottle. Watercolors is designed for sessionable sipping, providing a precisely-dosed, easy-to-control, uplifting experience that is perfect for those looking for an alcohol replacement. With a reported rapid onset effect of 15-minutes and offset of one hour, Calexo offers consumers the ability to control their dosing through a variety of delicious options. These products will be available for retail and home delivery in select California markets in three “colors”: Fuschia, Spring, and Sea. Calexo’s refreshed line of juice products, now in development, will include four all-natural, preservative-free flavours in convenient, recyclable aluminum cans. These products are made possible by the Company’s heat pasteurization tunnel, which enables shelf-stable drinks to be manufactured without preservatives. The Company believes it is the only such equipment available in a cannabis-licensed facility in California. “We are energized to collaborate with Calexo, a unique troupe of creative and social change-makers, to produce seven innovative, head-turning and smile-inducing drinks,” said Ted Zittell, a director of Tinley. “Calexo will benefit from the Company’s investment in industry-leading capabilities for infused-beverages across multiple manufacturing platforms, for classic glass bottles, mini-bottles, and cans. Our tunnel pasteurization capabilities enable new opportunities for preservative-free innovation—the perfect match for Calexo’s brand vision.” “We’re delighted to be collaborating with the Tinley team,” said Ian Colon, CEO of Calexo. “Tinley’s exceptional manufacturing facility offers special formulation and production solutions to uncompromising brands like Calexo. We’re looking forward to working together to expand our range of innovative beverages so that more people can experience Calexo’s delicious and health-conscious drinks.” Other Tinley’s Corporate Updates The Company is pleased to report progress on other facets of the Company’s operations: The 60-day notice period for Health Canada’s Notice of New Cannabis Products (NNCP) submitted for the Canadian versions of the Tinley's ’27™ products has now passed without issue. The Company experienced challenges with its Canadian bottle, which differs from the bottle it uses for these products in California. As a result, it was unable to meet a deadline for a provincial board’s purchase request. However, the Company has now received satisfactory test results for modified packaging, and it is therefore working to make these products available to all provincial buyers. The 60-day period for the NNCP’s submitted for Tinley’s carbonated, ready-to-drink products has not fully elapsed but is expected to do so on or about the first week of June.The Company has now received a purchase order from the previously-disclosed Tennessee distributor. The Company is working with Littman Brothers, one of the state’s most established beverage distributors, to sell in and promote all seven Beckett’s SKUs to on-premise and retail accounts, mainly in the Nashville area. Nashville is the #1 market for the Todd Chrisley television programs on NBCU’s USA Networks. Todd and his family will be supporting the brand’s growth through their television and social media assets, as well as through personal appearances throughout the city.BevMo!, recently acquired by national home delivery company GoPuff, has requested the new Beckett’s Tonics™ 12 fl. oz bottle format for all four of the Company’s ready-to-drink cocktails. These products are now in the process of shipping to BevMo’s stores throughout California.The Company has received the final permit required to complete the remaining tenant improvements on its Long Beach facility so that the Company can receive a distribution license from California’s Bureau of Cannabis Control. This additional licence will allow the Company to provide an additional service for its co-packing clients. The key benefits of this additional service include reducing the time needed to complete State compliance testing and permitting clients to select from a wider base of third-party distributors that do not have warehousing capabilities for beverages.The Company continues to progress through its co-packing client onboarding processes for the previously-disclosed pipeline of clients, as well as increase dispensary and mainstream store listings and home delivery options for its infused and non-infused branded products. The Company reminds constituents that it does not publicly disclose the financial or other details of its co-packing, distribution, influencer and other client and supplier agreements, in consideration of the interests of these parties and the Company, except if and as required by regulators. About Calexo Founded by artists and creatives in 2019, Calexo launched its first sparkling Cannabis drinks in 2020. The Calexo team reflects an intersectional prism of BIPOC, LGBTQ folks, women, immigrants and allies, working together to empower our communities through creative experiences. Calexo’s products include sparkling cannabis beverages made with all-natural fruit juices, botanicals and nano-emulsified THC, precisely dosed for an easy-to-control, uplifting experience that brings a smile to your mind. Calexo beverages are meant for sharing, sipping and savoring with rapid onset of 15-minutes and an offset of one hour. The brand is committed to always using carefully-selected, premium ingredients with no artificial flavors, sweeteners or colours. To learn more, visit www.calexo.co, high-five the brand on Instagram @drinkcalexo, or e-mail email@example.com. About The Tinley Beverage Company and Beckett’s Tonics The Tinley Beverage Company (OTC:TNYBF, CSE:TNY) manufactures the Becketts Classics™ and Beckett’s 27™ line of non-alcoholic, terpene-infused spirits and cocktails. Beckett’s products are available in mainstream food, beverage and specialty retailers, as well as online across the United States. Tinley also offers cannabis-infused versions of these products in licensed dispensaries throughout California. Expansion to Canada is underway for both product lines. Tinley’s facility in Long Beach California contains the state’s most versatile and technologically-advanced cannabis-licensed beverage manufacturing equipment. Please visit www.drinkbecketts.com, www.drinktinley.com, Instagram @drinktinleys and @drinkbecketts for recipes, product information and home delivery options. Forward-Looking Statements This press release contains or refers to forward-looking information and is based on current expectations that involve a number of business risks and uncertainties. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law. Products, formulations and timelines outlined herein are subject to change at any time. For further information on The Tinley Beverage Company and Beckett’s Tonics, please contact: The Tinley Beverage CompanyRichard Gillis(310) firstname.lastname@example.orgTwitter: @drinktinleys and @drinkbecketts Instagram: @drinktinleys and @drinkbecketts www.drinktinley.com OTC:TNYBF CSE:TNY A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/237e054c-3e55-4929-ad0e-69ce342c03f0
Shares of NVIDIA (NASDAQ: NVDA) climbed today while shares of rivals Intel (NASDAQ: INTC) and AMD (NASDAQ: AMD) dipped after NVIDIA unveiled a new CPU that will put competitive pressure on the latter companies in the important market for data center processors. NVIDIA kicked off its annual GPU Technology Conference (GTC) today with a slew of announcements, but the unveiling of a new CPU easily stole the show as the most meaningful new product. The company has long specialized primarily in GPUs instead of CPUs, and NVIDIA's prior efforts to develop CPUs have been lackluster.
Compass Minerals Snow Event Data and Salt Sales
Intel has laid out a plan to help automakers dealing with the global semiconductor shortage that has left companies like GM canceling production shifts.